Dengue 3 Human Infection Model (DENV-3)

Dengue Clinical Trial

Official title:

Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04298138
• Other study ID #: 2019-01-UMU
• Status: Completed
• Phase: Phase 1
• Start date: August 3, 2020
• Est. completion date: December 14, 2021

Study information

• Verified date: June 2022
• Source: State University of New York - Upstate Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.

Description:

Healthy subjects between 18 and 45 years old will be inoculated with Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) in a dose ranging study. Subjects will be closely monitored for the first 28 days with continued follow up through 6 months. Clinical and laboratory parameters, viremia and antibody levels will be assessed. The goal is to determine the dose that produces uncomplicated dengue-like illness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: December 14, 2021
• Est. primary completion date: December 14, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Age 18-45 at the time of consent

2. Ability and willingness to sign informed consent

3. Passing score on comprehension test of at least 75%, with up to 3 attempts

4. Available for the study period

5. Willing to use contraception for the duration of the study

6. Provide consent for release of medical history records from primary care physician, college or university, urgent care or emergency room visit

Exclusion Criteria:

1. Female: pregnant or lactating

2. Heavy menstrual bleeding within the last 6 months- menstrual periods lasting longer than 6 days, or requiring 5 or more pads or tampons per day.

3. Female subjects using an intrauterine device (IUD) or Mirena®

4. Female subjects with fibroids or uterine polyps, endometriosis, adenomyosis, and uterine scarring (e.g., after D&C)

5. Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1), hepatitis C, hepatitis B (assessed by HbsAg) virus, or positive antibodies to the flaviviruses (FV) dengue, West Nile, Yellow Fever, Japanese encephalitis, or Zika.

6. Active Diabetes or active peptic ulcer disease (PUD)

7. Chronic obstructive pulmonary disease (COPD) or coronary artery disease (CAD)

8. Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

9. Current, or a history of, auto-immune disease

10. History of Guillain-Barré syndrome (GBS)

11. Any history of FV infection or FV vaccination; or planned FV vaccination, outside the study protocol, during the study period

12. Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the subject from participating in the study.

13. Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits

14. Recent (in the past 4 weeks) travel to any dengue endemic area. These potential subjects may be eligible for enrollment a minimum of 4 weeks later

15. Any laboratory abnormalities prior to inoculation for the tests specified in Table 18 and Table 19 of the protocol, that are considered by the investigator to be clinically significant except those listed in exclusion criteria 16

16. Subjects with the following grade 2 or greater lab abnormalities: Creatinine; Liver Function Tests - ALT, AST; Hemoglobin (females and males); White Blood Cell (WBC) decrease; Platelets decreased; Prothrombin Time (PT); Partial Thromboplastin Time (PTT); Fibrinogen decrease

17. Significant screening physical examination abnormalities at the discretion of the investigator

18. Women who intend to become pregnant or men who intend to father a child during the study period (approximately 180 days)

19. Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous vaccination or an allergy to specific medications/animals for which antigens may be in the virus preparations to include: shellfish allergy, fetal bovine serum, L-glutamine, neomycin and streptomycin

20. Planning to donate blood in the 1 year following inoculation with dengue

21. Recent blood donation within prior 56 days of inoculation

22. Receipt of blood products or antibodies within 56 days of inoculation or during the study period

23. Participation (active or follow-up phase) or planned participation in another vaccine, drug, medical device, or medical procedure clinical trial in the 4 weeks prior to this trial, during the trial, or 6 months following inoculation in this clinical trial

24. Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation

25. Beliefs that bar the administration of blood products or transfusions

26. Positive urine screen for cocaine, amphetamines, or opiates

27. Currently taking Methadone or Suboxone

28. Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)

29. Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use

30. Chronic medical condition that, in the opinion of the investigator, impacts subject safety.

Related Conditions & MeSH terms

• Dengue

Intervention

Biological:
• Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Locations

Country	Name	City	State
United States	State University of New York, Upstate Medical University (SUNY-UMU)	Syracuse	New York

Sponsors (3)

Lead Sponsor	Collaborator
State University of New York - Upstate Medical University	U.S. Army Medical Research and Development Command, Walter Reed Army Institute of Research (WRAIR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Abnormal Laboratory Measurements	Total number of all abnormal labs	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Intensity of Abnormal Laboratory Measurements	Graded according clinical laboratory normals and FDA toxicity scale	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Duration of Abnormal Laboratory Measurements	Number of days of abnormal lab	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Occurrence of Solicited Injection Site Symptoms	Number of solicited symptoms	7 days post virus inoculation
Primary	Intensity of Solicited Injection Site Symptoms	Graded according to FDA toxicity scale	7 days post virus inoculation
Primary	Duration of Solicited Injection Site Symptoms	Number of days per symptom	7 days post virus inoculation
Primary	Occurrence of Unsolicited Injection Site Symptoms	Number of unsolicited site symptoms	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Intensity of Unsolicited Injection Site Symptoms	Graded according to FDA toxicity scale	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Duration of Unsolicited Injection Site Symptoms	Number of days per symptom	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Occurrence of Solicited Systemic Symptoms	Number of solicited systemic symptoms	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Intensity of Solicited Systemic Symptoms	Graded according to FDA toxicity scale	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Duration of Solicited Systemic Symptoms	Number of days per symptom	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Occurence of Unsolicited Systemic Symptoms	Number of unsolicited systemic symptoms	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Intensity of Unsolicited Systemic Symptoms	Graded according to FDA toxicity scale	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Duration of Unsolicited Systemic Symptoms	Number of days per symptom	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Number of Serious Adverse Events	Total number	28 days post virus inoculation or 7 days post hospitalization, whichever is later
Primary	Number of Serious Adverse Events	Total number	6 months post virus inoculation
Secondary	Incubation period before onset of fever	Number of days prior to fever	Up to 28 days post virus inoculation
Secondary	Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)	Levels of viremia	Up to 28 days post virus inoculation
Secondary	Occurence of fever	Defined as greater than or equal to 38°C (100.4°F) measured at least 2 times in 24 hours but not lasting more than 72 hours	Up to 28 days post virus inoculation
Secondary	Occurrence of Headache	Number of headaches	Up to 28 days post virus inoculation
Secondary	Grade of Headache	Graded according to FDA toxicity scale	Up to 28 days post virus inoculation
Secondary	Occurrence of Myalgia	Number of reported myalgias	Up to 28 days post virus inoculation
Secondary	Grade of Myalgia	Graded according to FDA toxicity scale	Up to 28 days post virus inoculation
Secondary	Occurrence of Rash	Number of rashes	Up to 28 days post virus inoculation
Secondary	Grade of Rash	Graded according to FDA toxicity scale	Up to 28 days post virus inoculation
Secondary	Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]	Number of abnormal liver function tests	Up to 28 days post virus inoculation
Secondary	Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]	Graded according clinical laboratory normals and FDA toxicity scale	Up to 28 days post virus inoculation
Secondary	Occurrence of Leukopenia	Number of occurrences	Up to 28 days post virus inoculation
Secondary	Grade of Leukopenia	Graded according clinical laboratory normals and FDA toxicity scale	Up to 28 days post virus inoculation
Secondary	Occurrence of Thrombocytopenia	Number of occurrences	Up to 28 days post virus inoculation
Secondary	Grade of Thrombocytopenia	Graded according clinical laboratory normals and FDA toxicity scale	Up to 28 days post virus inoculation